JP5269796B2 - ４種のデング血清型に対する免疫付与の方法 - Google Patents
４種のデング血清型に対する免疫付与の方法 Download PDFInfo
- Publication number
- JP5269796B2 JP5269796B2 JP2009530916A JP2009530916A JP5269796B2 JP 5269796 B2 JP5269796 B2 JP 5269796B2 JP 2009530916 A JP2009530916 A JP 2009530916A JP 2009530916 A JP2009530916 A JP 2009530916A JP 5269796 B2 JP5269796 B2 JP 5269796B2
- Authority
- JP
- Japan
- Prior art keywords
- vaccine
- den
- cyd
- serotype
- dengue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 206010012310 Dengue fever Diseases 0.000 title claims description 40
- 208000025729 dengue disease Diseases 0.000 title claims description 40
- 208000001490 Dengue Diseases 0.000 title claims description 36
- 238000000034 method Methods 0.000 title description 47
- 230000003053 immunization Effects 0.000 title description 10
- 238000002649 immunization Methods 0.000 title description 9
- 229960005486 vaccine Drugs 0.000 claims description 147
- 241000725619 Dengue virus Species 0.000 claims description 94
- 241000700605 Viruses Species 0.000 claims description 60
- 239000000203 mixture Substances 0.000 claims description 57
- 241000710829 Dengue virus group Species 0.000 claims description 9
- 230000001939 inductive effect Effects 0.000 claims description 6
- 238000002255 vaccination Methods 0.000 description 40
- 229940031416 bivalent vaccine Drugs 0.000 description 21
- 241000615954 Varroa destructor virus-1 Species 0.000 description 18
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 17
- 241000282693 Cercopithecidae Species 0.000 description 15
- 238000010790 dilution Methods 0.000 description 15
- 239000012895 dilution Substances 0.000 description 15
- 208000003152 Yellow Fever Diseases 0.000 description 14
- 206010058874 Viraemia Diseases 0.000 description 13
- 208000015181 infectious disease Diseases 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 241000282412 Homo Species 0.000 description 10
- 208000009714 Severe Dengue Diseases 0.000 description 10
- 230000002238 attenuated effect Effects 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 238000006386 neutralization reaction Methods 0.000 description 9
- 230000003472 neutralizing effect Effects 0.000 description 9
- 210000003501 vero cell Anatomy 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 101000708009 Homo sapiens Sentrin-specific protease 8 Proteins 0.000 description 7
- 206010037660 Pyrexia Diseases 0.000 description 7
- 102100031407 Sentrin-specific protease 8 Human genes 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 230000005847 immunogenicity Effects 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 238000011002 quantification Methods 0.000 description 6
- 230000005875 antibody response Effects 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 230000002458 infectious effect Effects 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 238000011529 RT qPCR Methods 0.000 description 4
- 208000015220 Febrile disease Diseases 0.000 description 3
- 241000710831 Flavivirus Species 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 210000000689 upper leg Anatomy 0.000 description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 241000256118 Aedes aegypti Species 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 101710091045 Envelope protein Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000282567 Macaca fascicularis Species 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 101710188315 Protein X Proteins 0.000 description 2
- 102100021696 Syncytin-1 Human genes 0.000 description 2
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 2
- 108020000999 Viral RNA Proteins 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 229940031351 tetravalent vaccine Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 206010003399 Arthropod bite Diseases 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 101100112679 Caenorhabditis elegans cyd-1 gene Proteins 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 241001227713 Chiron Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 101100169267 Escherichia coli (strain K12) cydA gene Proteins 0.000 description 1
- 101100169272 Escherichia coli (strain K12) cydB gene Proteins 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 241000710781 Flaviviridae Species 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 241000274177 Juniperus sabina Species 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 108010076039 Polyproteins Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 238000013381 RNA quantification Methods 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 229940124928 YF-Vax Drugs 0.000 description 1
- 241000710772 Yellow fever virus Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 229940031567 attenuated vaccine Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 210000000852 deltoid muscle Anatomy 0.000 description 1
- 201000002950 dengue hemorrhagic fever Diseases 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 238000003771 laboratory diagnosis Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 208000018555 lymphatic system disease Diseases 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000013178 mathematical model Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 229940031346 monovalent vaccine Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 210000003752 saphenous vein Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229940051021 yellow-fever virus Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0608660A FR2906724B1 (fr) | 2006-10-04 | 2006-10-04 | Methode d'immunisation contre les 4 serotypes de la dengue. |
| FR0608660 | 2006-10-04 | ||
| PCT/FR2007/052054 WO2008047023A2 (fr) | 2006-10-04 | 2007-10-02 | Methode d'immunisation contre les 4 serotypes de la dengue |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010505801A JP2010505801A (ja) | 2010-02-25 |
| JP2010505801A5 JP2010505801A5 (cg-RX-API-DMAC7.html) | 2010-10-28 |
| JP5269796B2 true JP5269796B2 (ja) | 2013-08-21 |
Family
ID=38222583
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009530916A Expired - Fee Related JP5269796B2 (ja) | 2006-10-04 | 2007-10-02 | ４種のデング血清型に対する免疫付与の方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US7718358B2 (cg-RX-API-DMAC7.html) |
| EP (3) | EP2077857B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5269796B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20090064593A (cg-RX-API-DMAC7.html) |
| CN (2) | CN101553251B (cg-RX-API-DMAC7.html) |
| AR (1) | AR063057A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2007311792B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0719849A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2663885A1 (cg-RX-API-DMAC7.html) |
| FR (1) | FR2906724B1 (cg-RX-API-DMAC7.html) |
| IL (2) | IL197768A0 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2009003417A (cg-RX-API-DMAC7.html) |
| TW (2) | TWI406673B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2008047023A2 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA200901816B (cg-RX-API-DMAC7.html) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5227172B2 (ja) * | 2005-08-10 | 2013-07-03 | サノフィ パスツール バイオロジクス リミテッド ライアビリティ カンパニー | デングウイルス感染に対するワクチン接種 |
| FR2903605A1 (fr) * | 2006-07-12 | 2008-01-18 | Sanofi Pasteur Sa | Methode d'immunisation contre les quatres serotypes de la dengue |
| FR2909286B1 (fr) * | 2006-12-01 | 2012-06-08 | Sanofi Pasteur | Methode d'immunisation contre les 4 serotypes de la dengue |
| ES2615390T3 (es) | 2008-03-05 | 2017-06-06 | Sanofi Pasteur | Proceso para estabilizar una composición de vacuna que contiene adyuvante |
| EP2143440A1 (fr) * | 2008-07-09 | 2010-01-13 | Sanofi Pasteur | Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués |
| MX343172B (es) * | 2009-06-01 | 2016-10-26 | Takeda Vaccines Inc | Composiciones y metodos para administracion de vacunas contra virus del dengue. |
| US8968996B2 (en) | 2009-06-01 | 2015-03-03 | Takeda Vaccines, Inc. | Compositions and methods for rapid immunization against dengue virus |
| AU2010286368B2 (en) | 2009-08-31 | 2015-09-03 | Gen-Probe Incorporated | Dengue virus assay |
| EP2353609A1 (en) * | 2010-02-04 | 2011-08-10 | Sanofi Pasteur | Immunization compositions and methods |
| EP2550298B1 (en) * | 2010-03-23 | 2015-07-15 | The Regents of The University of California | Compositions and methods for self-adjuvanting vaccines against microbes and tumors |
| US9637521B2 (en) * | 2011-06-29 | 2017-05-02 | Emergex Vaccines Holdings Limited | Cytotoxic T lymphocyte inducing immunogens for prevention treatment and diagnosis of dengue virus infection |
| TW201402143A (zh) * | 2012-06-10 | 2014-01-16 | Inviragen Inc | 抗登革熱病毒疫苗之組成物及投藥方法 |
| US8895028B2 (en) * | 2012-07-20 | 2014-11-25 | Arbovax, Inc. | Methods and compositions for dengue virus 3 (DV3) infectious clone |
| PE20150356A1 (es) | 2012-07-24 | 2015-03-20 | Sanofi Pasteur | Composiciones de vacuna para la prevencion contra la infeccion por el virus del dengue |
| US20150196631A1 (en) * | 2012-07-24 | 2015-07-16 | Sanofi Pasteur | Vaccine compositions |
| WO2014083194A1 (en) | 2012-11-30 | 2014-06-05 | Sanofi Pasteur | Methods for inducing antibodies |
| US9878031B2 (en) | 2012-12-14 | 2018-01-30 | Takeda Vaccines, Inc. | Compositions, methods of administration and uses for trivalent dengue virus formulations |
| JP2016523251A (ja) | 2013-06-21 | 2016-08-08 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | デングウイルスワクチン組成物およびその使用方法 |
| TWI852899B (zh) | 2014-09-02 | 2024-08-21 | 法商賽諾菲巴斯德公司 | 疫苗組合物 |
| AU2015369875A1 (en) | 2014-12-22 | 2017-06-15 | Merck Sharp & Dohme Corp. | Dengue virus vaccine compositions and methods of use thereof |
| US10857222B2 (en) | 2015-07-03 | 2020-12-08 | Sanofi Pasteur | Concomitant dengue and yellow fever vaccination |
| KR102297300B1 (ko) * | 2015-11-27 | 2021-09-02 | 케이엠 바이올로직스 가부시키가이샤 | 뎅기 바이러스 약독주를 뱅크화한 생바이러스, 및 그것들을 항원으로 하는 뎅기 백신 |
| EP3691681A1 (en) | 2017-10-05 | 2020-08-12 | Sanofi Pasteur | Compositions for booster vaccination against dengu |
| PE20211545A1 (es) | 2018-09-05 | 2021-08-16 | Takeda Vaccines Inc | Dosis unitaria de vacuna contra el dengue y administracion de esta |
| CN114555113A (zh) | 2019-08-16 | 2022-05-27 | 武田疫苗股份有限公司 | 用于预防登革热和甲型肝炎的方法 |
| US20240076631A2 (en) | 2020-02-27 | 2024-03-07 | Takeda Vaccines, Inc. | Method for removing host cell dna from virus preparation |
| WO2023147337A2 (en) | 2022-01-25 | 2023-08-03 | Takeda Vaccines, Inc. | Large-scale flaviviral vaccine production and manufacture |
| US20250177511A1 (en) | 2022-02-15 | 2025-06-05 | Takeda Vaccines, Inc. | Dengue vaccine batch mixing process |
| WO2023215383A1 (en) | 2022-05-04 | 2023-11-09 | Takeda Vaccines, Inc. | Computer-based determination of flavivirus infectivity |
| EP4375381A1 (en) | 2022-11-18 | 2024-05-29 | Takeda Vaccines, Inc. | A method for determining the proportion of a live, attenuated flavivirus having a nucleotide sequence comprising at least one attenuation locus in a formulation |
| WO2024118740A1 (en) | 2022-11-29 | 2024-06-06 | Takeda Vaccines, Inc. | Large-scale flaviviral vaccine production and manufacture |
| WO2025072259A1 (en) | 2023-09-25 | 2025-04-03 | Takeda Vaccines, Inc. | Coadministration of tetravalent dengue vaccine with hpv vaccine |
| WO2025122855A1 (en) | 2023-12-08 | 2025-06-12 | Takeda Vaccines, Inc. | A method for determining the concentration of residual vero cell genomic dna in a sample containing virus obtained from production in vero cells |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996040933A1 (en) | 1995-06-07 | 1996-12-19 | The Government Of The United States Of America, Represented By The Secretary Department Of Health And Human Services | Infectious dengue 2 virus pdk-53 as quadravalent vaccine |
| NZ337522A (en) | 1997-02-28 | 2001-02-23 | St | Chimeric flavivirus incorporating yellow fever virus modified such that a prM-E protein of a second flavivirus is expressed, and vaccines for flavivruses |
| EP1080370A4 (en) | 1998-05-29 | 2003-07-30 | Epimmune Inc | IDENTIFICATION OF RESILIENT DR EPITOPES LARGELY REACTIVE |
| AU4179200A (en) | 1999-03-26 | 2000-10-16 | Walter Reed Army Institute Of Research | Attenuated dengue-1 virus vaccine |
| EP1165128A2 (en) | 1999-03-26 | 2002-01-02 | Walter Reed Army Institute of Research | Attenuated dengue-2 virus vaccine |
| ES2322327T3 (es) | 1999-03-26 | 2009-06-19 | Walter Reed Army Institute Of Research | Vacuna multivalente contra el virus del dengue. |
| EP1165130A2 (en) | 1999-03-26 | 2002-01-02 | Walter Reed Army Institute of Research | Attenuated dengue-3 virus vaccine |
| WO2000057910A1 (en) * | 1999-03-26 | 2000-10-05 | Walter Reed Army Institute Of Research | Attenuated dengue-4 virus vaccine |
| US6632663B1 (en) | 1999-09-22 | 2003-10-14 | Aventis Pasteur Limited | DNA immunization against chlamydia infection |
| EP1263965B1 (en) | 2000-02-16 | 2011-09-28 | The Government of the United States of America, as represented by the Secretary, Department of Health & Human Services | Avirulent, immunogenic flavivirus chimeras |
| EP1159969A1 (fr) | 2000-05-30 | 2001-12-05 | Aventis Pasteur | Vaccine composition |
| DK1159968T3 (da) * | 2000-05-30 | 2009-02-23 | Univ Mahidol | Attenuerede stammer af Dengue-virus og deres anvendelse i en vaccinesammensætning |
| AT410634B (de) | 2001-02-21 | 2003-06-25 | Franz X Dr Heinz | Attenuierte lebendimpfstoffe |
| EP1402075B1 (en) | 2001-05-22 | 2012-11-14 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, the Department of Health and Human Services, | Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses |
| KR20040004642A (ko) | 2001-05-23 | 2004-01-13 | 덴드레온 샌 디에고 엘엘씨 | 세포 표면 프로테아제에 의해 활성화되는 접합체 및 이의치료학적 용도 |
| PL371187A1 (en) | 2001-06-01 | 2005-06-13 | Acambis, Inc. | Chimeric flavivirus vectors |
| US20040120964A1 (en) * | 2001-10-29 | 2004-06-24 | Mikszta John A. | Needleless vaccination using chimeric yellow fever vaccine-vectored vaccines against heterologous flaviviruses |
| AU2003267937C1 (en) * | 2002-01-15 | 2019-08-08 | Sanofi Pasteur Biologics, Llc | Flavivirus vaccines |
| WO2003101397A2 (en) * | 2002-05-31 | 2003-12-11 | Acambis, Inc. | Tetravalent dengue vaccines |
| BRPI0408774A (pt) | 2003-03-24 | 2006-03-28 | Scripps Research Inst | vacinas de dna contra crescimento tumoral e seus usos |
| CA2611934C (en) * | 2005-06-17 | 2015-11-03 | Sanofi Pasteur | Dengue serotype 1 attenuated strain |
| JP5227172B2 (ja) * | 2005-08-10 | 2013-07-03 | サノフィ パスツール バイオロジクス リミテッド ライアビリティ カンパニー | デングウイルス感染に対するワクチン接種 |
| FR2903605A1 (fr) * | 2006-07-12 | 2008-01-18 | Sanofi Pasteur Sa | Methode d'immunisation contre les quatres serotypes de la dengue |
| FR2909286B1 (fr) | 2006-12-01 | 2012-06-08 | Sanofi Pasteur | Methode d'immunisation contre les 4 serotypes de la dengue |
-
2006
- 2006-10-04 FR FR0608660A patent/FR2906724B1/fr not_active Expired - Fee Related
-
2007
- 2007-09-20 TW TW096135167A patent/TWI406673B/zh not_active IP Right Cessation
- 2007-09-20 TW TW102119488A patent/TW201336508A/zh unknown
- 2007-09-28 AR ARP070104316A patent/AR063057A1/es unknown
- 2007-10-02 ZA ZA200901816A patent/ZA200901816B/xx unknown
- 2007-10-02 WO PCT/FR2007/052054 patent/WO2008047023A2/fr not_active Ceased
- 2007-10-02 AU AU2007311792A patent/AU2007311792B2/en not_active Ceased
- 2007-10-02 CN CN2007800444299A patent/CN101553251B/zh not_active Expired - Fee Related
- 2007-10-02 EP EP07858487.7A patent/EP2077857B1/fr not_active Not-in-force
- 2007-10-02 US US11/866,382 patent/US7718358B2/en not_active Expired - Fee Related
- 2007-10-02 KR KR1020097008657A patent/KR20090064593A/ko not_active Abandoned
- 2007-10-02 CA CA002663885A patent/CA2663885A1/en not_active Abandoned
- 2007-10-02 EP EP11192672A patent/EP2526965A1/fr not_active Withdrawn
- 2007-10-02 MX MX2009003417A patent/MX2009003417A/es active IP Right Grant
- 2007-10-02 EP EP11192665A patent/EP2526964A1/fr not_active Withdrawn
- 2007-10-02 CN CN201310128837XA patent/CN103285386A/zh active Pending
- 2007-10-02 JP JP2009530916A patent/JP5269796B2/ja not_active Expired - Fee Related
- 2007-10-02 BR BRPI0719849-3A2A patent/BRPI0719849A2/pt active Search and Examination
-
2009
- 2009-03-23 IL IL197768A patent/IL197768A0/en not_active IP Right Cessation
-
2010
- 2010-03-05 US US12/718,308 patent/US20100270202A1/en not_active Abandoned
-
2013
- 2013-02-04 IL IL224572A patent/IL224572A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| TW201336508A (zh) | 2013-09-16 |
| IL197768A0 (en) | 2011-08-01 |
| AR063057A1 (es) | 2008-12-23 |
| CN101553251A (zh) | 2009-10-07 |
| EP2077857B1 (fr) | 2013-11-20 |
| BRPI0719849A2 (pt) | 2014-04-29 |
| US7718358B2 (en) | 2010-05-18 |
| CN101553251B (zh) | 2013-05-22 |
| CA2663885A1 (en) | 2008-04-24 |
| MX2009003417A (es) | 2009-04-09 |
| CN103285386A (zh) | 2013-09-11 |
| EP2526965A1 (fr) | 2012-11-28 |
| EP2077857A2 (fr) | 2009-07-15 |
| KR20090064593A (ko) | 2009-06-19 |
| AU2007311792B2 (en) | 2013-05-02 |
| FR2906724A1 (fr) | 2008-04-11 |
| TW200826959A (en) | 2008-07-01 |
| WO2008047023A2 (fr) | 2008-04-24 |
| WO2008047023A3 (fr) | 2008-10-23 |
| FR2906724B1 (fr) | 2009-03-20 |
| JP2010505801A (ja) | 2010-02-25 |
| TWI406673B (zh) | 2013-09-01 |
| EP2526964A1 (fr) | 2012-11-28 |
| IL224572A (en) | 2014-06-30 |
| AU2007311792A1 (en) | 2008-04-24 |
| ZA200901816B (en) | 2010-06-30 |
| US20080085288A1 (en) | 2008-04-10 |
| US20100270202A1 (en) | 2010-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5269796B2 (ja) | ４種のデング血清型に対する免疫付与の方法 | |
| JP5269803B2 (ja) | デング熱の４種の血清型に対する免疫付与のプロトコル | |
| JP5295956B2 (ja) | ４種のデング熱血清型に対する免疫付与の方法 | |
| US8067565B2 (en) | Dengue serotype 1 attenuated strain | |
| CA2611954C (en) | Dengue serotype 2 attenuated strain |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100414 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100907 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100907 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20120309 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120911 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20121210 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20121217 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130109 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130409 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130508 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |